An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044
Condition: Rheumatoid Arthritis
MeSH terms: Arthritis; Arthritis, Rheumatoid
Intervention: Certolizumab Pegol
Intervention description: Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
Intervention MeSH terms: Certolizumab Pegol
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 347.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Rheumatoid Arthritis; TNFα antagonist; Certolizumab pegol; Chinese patients; Open-label

Summary:

      This study will continue to evaluate the safety & efficacy of Certolizumab Pegol (CZP) for 6
      months in Chinese subjects with active Rheumatoid Arthritis who participated in RA0044.
    

Eligibility criteria:

        Inclusion Criteria:

          -  An Institutional Review Board (IRB)/ Independent Ethics Committee (IEC) approved
             written Informed Consent form (ICF) for RA0078 is signed and dated by the subject or
             by the parent(s) or legal representative

          -  Subject/ legal representative is considered reliable and capable of adhering to the
             protocol (eg, able to understand and complete diaries), visit schedule, and medication
             intake according to the judgment of the Investigator

          -  Subjects must either have:

               -  Completed RA0044 through Week 24, OR

               -  Failed to achieve an ACR20 response at Week 12 (confirmed at Week 14) in RA0044

          -  Subjects must have complied with the protocol requirements during their participation
             in RA0044

          -  Subjects entering RA0078 who have completed RA0044 must have a clear chest x-ray at
             the Week 24 Completion Visit of RA0044. Subjects who enter RA0078 at Week 16 of the
             RA0044 study are not required to have a chest x-ray prior to enrollment

          -  Subject is able to continue treatment with Methotrexate (MTX) (with or without folic
             acid) at a dose deemed appropriate by the Investigator

          -  Female subjects with childbearing potential should have a negative pregnancy test at
             Entry and should have a medically accepted method of contraception used during the
             entire duration of the study and for 10 weeks after the last dose of Certolizumab
             pegol (CZP). Medically accepted methods of contraception are: hormonal contraception
             for at least 2 cycles prior to Screening, intrauterine device, implant device,
             diaphragm with spermicide, bilateral tubal ligation, monogamous relationship with
             vasectomized (for at least 3 months prior to Screening) partner, or using condoms with
             spermicide gel. Abstinence is not an acceptable method of contraception for the study.
             Female subjects who are postmenopause for at least 2 years or had undergone a complete
             hysterectomy, bilateral tubal ligation and/ or bilateral ovariectomy, or have a
             congenital sterility are considered not of childbearing potential. Male subjects must
             agree to ensure they use adequate contraception during the study and for at least 10
             weeks after the subject receives their last dose of study medication

        Exclusion Criteria:

        Rheumatoid Arthritis (RA) disease-related exclusions:

          -  Subjects have a diagnosis of any other inflammatory arthritis eg, psoriatic arthritis
             or ankylosing spondylitis

          -  Subjects have a secondary, noninflammatory type of arthritis (eg, osteoarthritis or
             fibromyalgia) that in the Investigator's opinion is symptomatic enough to interfere
             with evaluation of the effect of CZP on the subject's primary diagnosis of RA

          -  Subjects have a history of an infected joint prosthesis at any time with that
             prosthesis still in situ

        Concomitant medication exclusions

          -  Subjects must be free of the following concomitant medications:

               -  Any biological therapy for RA

               -  Any experimental therapy, within or outside a clinical trial (except RA0044)

               -  Live vaccines Medical history exclusions

          -  Lactating and/or pregnant female subjects

          -  Male subjects with childbearing potential partner(s) and female subjects of
             childbearing potential who are NOT practicing effective birth control. All female
             subjects must test negative on a urine pregnancy test before study entry and at each
             study visit

          -  Subjects with known TB infection, at high risk of acquiring TB infection, or latent TB
             (LTB) infection (with exception) are excluded

          -  Subjects who had 3 or more infections requiring systemic antibiotics during RA0044

          -  Subjects with a history of chronic infection, recent serious or life-threatening
             infection (within 6 months, including herpes zoster), or a current sign or symptom
             that may indicate an infection (eg, fever, cough)

          -  Subjects with a history or active systemic/ respiratory infection due to fungal,
             parasitic, or mycotic pathogens including but not limited to histoplasmosis,
             coccidiosis, paracoccidiosis, pneumocystis, blastomyces, aspergillus, and
             nontuberculous mycobacteria (NTMB)

          -  Radiographic evidence suggestive of any of these infections is sufficient grounds for
             exclusion

          -  Subjects at a high risk of infection in the Investigator's opinion (eg, subjects with
             leg ulcers, indwelling urinary catheter, and persistent or recurrent chest infections,
             and subjects who are permanently bedridden or wheelchair bound)

          -  Subjects with a known positive hepatitis B surface antigen (HBsAg) test and/ or
             hepatitis C virus antibody (anti-HCV) test result

          -  Subjects with known human immunodeficiency virus (HIV) infection

          -  Subjects with lymphoproliferative disorder including lymphoma or signs and symptoms
             suggestive of lymphoproliferative disease at any time

          -  Subjects with active malignancy of any type

          -  Subjects with a history of blood dyscrasias, eg, leukemia or hemophilia where the
             blood constituents are abnormal or are present in abnormal quantity.

          -  Subjects with class III or IV congestive heart failure New York Heart Association
             (NYHA) 1994

          -  Subjects with suspected or diagnosed demyelinating disease of the central nervous
             system (eg, multiple sclerosis or optic neuritis)

          -  Subjects with a current or recent history, as determined by the Investigator, of
             severe, progressive, and/or uncontrolled renal, hepatic, hematological,
             gastrointestinal, endocrine, pulmonary, cardiac, neurological, or cerebral disease
             which would interfere with the subject's participation in the study. Abnormal
             laboratory parameters that require exclusion of a subject are detailed in protocol

          -  Subjects with an adverse reaction to Percutaneous Endoscopic Gastrostomy (PEG) or a
             protein medicinal product or known hypersensitivity to any components of the study
             medication or comparative drugs as stated in this protocol